Peptide Classifiers for Rheumatoid Arthritis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing rheumatoid arthritis (RA) lack comprehensive and unbiased profiling of serum antibodies against the human proteome, including citrullinome and homocitrullinome, leading to suboptimal diagnostic and prognostic accuracy.
Innovation Solution
A system and method for epitope-level characterization of autoantibodies using a peptide library including native and citrullinated/homocitrullinated peptides, which identifies a set of peptide features for constructing classifiers with improved sensitivity and specificity for RA diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If protein arrays are used to retain native 3D conformation, then structural integrity is improved, but enzymatic conversion of arginine and lysine to citrulline and homocitrulline remains incomplete
Solution Approach 1:
The patent extracts the problematic enzymatic conversion step and replaces it with chemically synthesized peptides that already contain citrulline and homocitrulline residues. This eliminates the incomplete conversion issue while maintaining the ability to study autoantibody reactivity against modified proteins.
Solution Approach 2:
The patent creates synthetic copies of citrullinated and homocitrullinated peptides through chemical synthesis rather than enzymatic modification. These synthetic peptides accurately replicate the target structures without relying on incomplete enzymatic conversion, providing reliable profiling of autoantibody repertoires.
2Manufacturing precision
If peptide arrays are used to incorporate citrulline and homocitrulline during synthesis, then conversion efficiency is improved, but citrulline specific antibody reactivity may be conflated with incomplete arginine conversion
Solution Approach 1:
The patent introduces a controlled chemical synthesis process as an intermediary step that precisely incorporates citrulline and homocitrulline residues at defined positions. This intermediary approach ensures complete and accurate incorporation without the ambiguity of enzymatic conversion, allowing clear distinction between true citrulline-specific reactivity and artifacts from incomplete arginine conversion.
3Measurement precision
If comprehensive profiling of serum antibodies against entire human proteome is performed, then diagnostic accuracy is improved, but complexity of the system increases
Solution Approach 1:
The patent segments the comprehensive proteome into manageable peptide components, synthesizing and analyzing individual citrullinated and homocitrullinated peptides separately. This segmentation allows systematic profiling of autoantibody repertoires across the entire proteome while maintaining experimental control and data interpretability, ultimately achieving high diagnostic accuracy without overwhelming system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach provides a comprehensive profiling of RA serum antibodies, resulting in peptide classifiers that exceed the performance of current gold-standard tests in terms of sensitivity and specificity, enabling more accurate RA diagnosis and prognosis.
Implementation Method 1
Antibody binding to its cognate antigen is achieved through non-covalent interactions between the complementarity determining regions (CDR) of the antibody against conformation adopted by the antigen
Data Source
AI summary
The present disclosure provides for compositions and methods for identifying peptide classifiers. In one embodiment, a peptide classifier for diagnosing rheumatoid arthritis includes a composition comprising a plurality of molecules. Each molecule comprises a peptide having a sequence selected from SEQ ID NOS: 1-8861, wherein the plurality of molecules defines a classifier for rheumatoid arthritis.